CND Life Sciences has received FDA Breakthrough Device Designation for its Syn-One Test, designed to aid in diagnosing synucleinopathies in patients aged 40 years and above with neurological symptoms.
Todd Levine | 09/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy